| Document |
Document Title |
|
WO/2007/045572A1 |
The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R1, R2, R3, R4, R5 and X are as herein de...
|
|
WO/2007/041837A1 |
This invention relates to a novel class of compounds, represented by the formula (I) below, wherein the meanings of Rl, R2, R3, R4, R5, R6, R7, X and Y are indicated therein, which are cysteine protease inhibitors, including but not limi...
|
|
WO/2007/042418A2 |
The instant invention discloses a process for preventing contact discoloration of substrates coming into contact with elastomers and stabilizing elastomers to prevent oxidative, thermal, dynamic, light-induced and/or ozone-induced degrad...
|
|
WO/2007/043568A1 |
A drug, specifically, a novel arylamidrazone derivative having an antagonistic effect on an S1P3 receptor; and a medicine containing the drug as an active ingredient. The drug is an arylamidrazone derivative represented by the following ...
|
|
WO/2007/039741A1 |
The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.
|
|
WO/2007/039127A1 |
The invention relates to a process for the preparation of bicalutamide (I) which comprises oxidizing N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)thi
o]-2-hydroxy-2-methyl-propanamide (II) in a solution of peracetic acid in a...
|
|
WO/2007/039736A1 |
The invention relates to substituted phenylacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.
|
|
WO/2007/034755A1 |
Compounds exerting high activities against various destructive insects and/or mites in agricultural and horticultural field, particularly excellent miticidal activity against Panonychus citri which is a weighty pest to citrus fruits, nam...
|
|
WO/2007/031608A1 |
The present invention relates to a refined and detailed molecular model of the α2β1 integrin l-domain, especially the MIDAS and to the use of such a model for designing novel integrin modulators, especially α2β1 integrin modulators. ...
|
|
WO/2007/033266A2 |
Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-
dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of m...
|
|
WO/2007/030567A2 |
Compounds are described that are active on at least one of PPARα, PPARδ, and PPARγ, which are useful for therapeutic and/or prophylactic methods involving modulation of at least one of PPARα, PPARδ, and PPARγ.
|
|
WO/2007/025575A1 |
A compound of Formula (I).
|
|
WO/2007/020381A2 |
A process for the preparation of a compound of formula (I) wherein: R is an alkynyl group; R1 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, phenyl and phenylalkyl, it being possible in turn for all of the receding groups to c...
|
|
WO/2007/012183A1 |
A process which includes the reacting of sodium perborate with N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)thi
o]-2-hydroxy- 2-methylpropanamide to form bicalutamide. Said process may comprise the reaction of N-[4-cyano-3-(t...
|
|
WO/2007/009250A1 |
The present invention relates to novel renin inhibitors of the general Formula (I), and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes fo...
|
|
WO/2007/003965A1 |
The present invention relates to the compounds of formula (I): wherein A,B, n, X, Y, Z, R1, R2, R3, R4, R5, R6, R7 and R8 are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them and ...
|
|
WO/2007/001245A2 |
A method for improving the lubricating properties of a isomerized distillate base oil having a kinematic viscosity at 100 degrees C between about 2.5 cSt and about 8 cSt, the method comprising blending with said isomerized distillate bas...
|
|
WO/2006/138660A2 |
The invention relates to substituted adamantane compounds of formula (I), pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferati...
|
|
WO/2006/137395A1 |
Disclosed are a compound represented by the general formula (1) below which exhibits a high insecticidal effect, and a pesticide containing such a compound as an active ingredient. (1) (In the formula, A1, A2, A3 and A4 respectively repr...
|
|
WO/2006/136135A2 |
The invention relates to a method for decarboxylating C-C cross-linking by reacting carboxylic salts with carbon electrophiles in the presence of transition metal compounds as catalysts. The method represents a decarboxylating cross-coup...
|
|
WO/2006/137376A1 |
Disclosed is a compound having high pesticidal effects which is represented by the general formula (1) below. Also disclosed is a pesticide containing such a compound as an active ingredient. (1) (In the formula, A1, A2, A3 and A4 respec...
|
|
WO/2006/133823A1 |
Benzanilides of the formula: (I) in which X represents hydrogen, halogen, nitro, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl or C1-6 alkylsulfonyloxy; Y represents halogen or C1-6 alkyl; R1 represents C1-6 alkyl, C1-6 alkylthi...
|
|
WO/2006/134040A1 |
The invention is concerned with novel anthranilic acid derivatives of formula (I) wherein R1 to R14, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compo...
|
|
WO/2006/134341A1 |
A compound of the formula (I): wherein R1,R2,R3, R4,Ar, A, n and m are defined herein, is disclosed as a GlyT1 inhibitor; pharmaceutical compositions containing the compound of the formula (I) are also disclosed as are their use in medic...
|
|
WO/2006/131713A1 |
The present invention provides compounds of formula (I): wherein R1 is an alkyl, phenyl, heterocyclyl, cycloalkyl, alkoxy, ester, amino or amide group; R2 is a phenyl, heterocyclyl, alkyl, cycloalkyl or cycloalkylalkyl group; R3 is an al...
|
|
WO/2006/131465A1 |
The present invention pertains to a reversibly thermochromic system comprising a substituted or an unsubstituted 6,11-dihydroxy-naphthacene-5,12-dione and a base and to a reversibly thermochromic composition comprising the reversibly the...
|
|
WO/2006/131711A1 |
The present invention provides compounds of formula I: wherein R1 is an alkyl, phenyl, heterocyclyl, cycloalkyl, alkoxy, ester, amino or amide group; R2 is a phenyl, heterocyclyl, alkyl, cycloalkyl or cycloalkylalkyl group; R3 is an alky...
|
|
WO2006097817A9 |
This invention provides a compound of the formula (I) or a pharmaceutically acceptable salt or solvate thereof. These compounds are useful for the treatment of disease conditions caused by overactivation of VR1 receptor such of pain, or ...
|
|
WO/2006/128287A1 |
The present invention provides compounds of formula I which are inhibitors of cathepsin S and as such are useful in the prevention and treatment of cathepsin S dependent diseases and conditions including, but not limited to, chronic obst...
|
|
WO/2006/125593A1 |
A compound of formula (I); in free or pharmaceutically acceptable salt form, where R1, R2, R3, R4, R5, m, n, w, X, Y and Q have the meanings as indicated in the specification, are useful for treating conditions mediated by the CRTh2 rece...
|
|
WO/2006/125688A1 |
The invention relates to benzoyl-substituted serine amides of formula (I), in which the variables R1 to R11 are defined as cited in the description and to their salts that can be used for agricultural purposes. The invention also relates...
|
|
WO/2006/124875A2 |
Compounds of Formula (I), or pharmaceutically acceptable salts thereof, are provided, which are modulators of secreted frizzled related protein-1. The compounds, and compositions containing the compounds, can be used to treat a variety o...
|
|
WO/2006/120178A1 |
The present invention relates to compounds of formula I, in which at least one of R5, R6 and R7 is SR12, S(O)R12 or S(O)2R12 group where R12 is a C1-6haloalkyl group, that act, as chemical uncouplers. Compounds of the invention are usefu...
|
|
WO2006093823A9 |
This invention provides aryl and heteroaryl compounds of formula (X). The compounds of the invention may be useful as antagonists, or partial antagonist of factor IX and/or factor Xl and thus, may be used to inhibit the intrinsic pathway...
|
|
WO/2006/114262A1 |
The invention provides compounds of formula (I) wherein R1 represents hydrogen or alkyl; R2 represents an unsubstituted or substituted heterocycle or R2 represents an unsubstituted or substituted aryl; R3 represents alkyl or halogen; X r...
|
|
WO/2006/112742A2 |
Invention relates to the process for preparation of 13,14-dihydro-PGF2&agr derivatives of R or S configuration at carbon atom in omega chain substituted by hydroxyl, represented by formula (I), wherein the meaning of substituents is defi...
|
|
WO/2006/108695A2 |
The invention relates to macrocyclic sulfoximines of the general Formula I : (I), wherein A, X, Y, R1, R2 and R3 have the meaning as given in the specification and the claims, and to salts thereof; to pharmaceutical compositions comprisi...
|
|
WO/2006/106954A1 |
A novel herbicide which has an excellent herbicidal effect and is usable in a wide range of applications including agricultural lands and nonagricultural lands and applicable by various methods, e.g., soil treatment and stalk/leaf treatm...
|
|
WO/2006/100502A1 |
There is provided a compound having Formula (I ) R1-Z-R2 wherein R1 is a group selected from optionally substituted fused polycyclic groups, substituted alkyl groups, branched alkyl groups, and optionally substituted cycioalkyl groups Z ...
|
|
WO/2006/097766A1 |
Compounds of formula (I) are potent and selective antagonists of the 5-HT2A receptor, and hence are useful in treatment of various CNS disorders.
|
|
WO/2006/098308A1 |
An anthranilic acid derivative represented by the general formula below or a salt thereof: wherein R1 and R2 independently represent a hydrogen atom or the like; R3 represents a phenyl, cycloalkyl or bicyclic heterocyclic group which may...
|
|
WO/2006/087718A1 |
New compounds, inhibiting protein tyrosine kinases (PTKs) or steroid-related enzymes (SREs), which affect apoptosis in malignant tissues, and can be used in the preparation of medicaments for treating various disorders, and for elongatin...
|
|
WO/2006/082010A1 |
Provided herein are compounds of the formula (I), as well as pharmaceutically acceptable salts thereof, wherein R1, R2, R2´, R3, R4, R5 and X are as defined in the specification and claims. These compounds, and the pharmaceutical compos...
|
|
WO/2006/074244A2 |
The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzy...
|
|
WO/2006/070862A1 |
A process by which 5-deoxy-L-arabinose, which is important as a material for the production of saproterin, a useful therapeutic agent for atypical hyperphenylalaninemia, can be industrially and efficiently produced even with a simple pro...
|
|
WO/2006/068897A2 |
A premium wear resistant lubricant comprises a base stock, preferably a GTL liquid or the liquid isomerization product of slack wax or F-T wax, and a non-ionic ashless anti-wear additive. The non-ionic ashless antiwear additive is prefer...
|
|
WO/2006/066790A1 |
Compounds of the formula (I), or pharmaceutically acceptable salts thereof, wherein R2 is (CR3R4)n-NR5R6 and m, p, q, Ar, R1, R3, R4, R5 and R6 are as defined in the claims, which are selective antagonists of 5-HT6 and/or 5-HT2A. Also pr...
|
|
WO/2006/064054A1 |
Process for the treatment of wetwhite, wetblue or vegetable pretanned leather, characterized in that - for the purpose of said treatment - a composition containing a) 1 - 95% by weight of a product of the reaction of a phenol and a sulph...
|
|
WO/2006/062093A1 |
An anthranilic acid derivative represented by the general formula (X) [wherein R1 represents hydrogen or a carboxy-protecting group; R2 represents optionally substituted phenyl, a heterocyclic group, etc.; R3 represents optionally substi...
|
|
WO/2006/059149A1 |
Compounds of formula (I) are potent and selective 5-HT2A antagonists, useful in treatment of a variety of adverse conditions of the CNS.
|
